Tagged with GI

Opinion An examination of the evolution of the pharma data supply chain and the vital importance of establishing trust with patients to access complete information sets from Matt Sinderbrand, formerly CEO of Betterpath Health and now SVP and chief product officer at Hu-manity.co.   Now that we have all this data,…

Spain With cost pressures mounting, Spain is increasingly turning towards digital solutions to maintain the high levels of care provided by its healthcare system.   Spain is at a point of disruption in which the healthcare system is facing big challenges; the solution to which has to be technology Angeles Delgado,…

Korea French-headquartered logistics and distribution provider Bolloré Logistics has been steadily increasing its footprint in Korean life sciences in recent years – attaining international certifications to assure potential partners of their commitment to quality and working closely with some of the country’s top domestic conglomerates as they make the move into…

FT These insights come from Richie Etwaru, the CEO of Hu-Manity.co, known for pursuing the 31st Human Right “everyone has the right to legal ownership of their inherent human data as property.”    There is a tremendously broken data supply chain, which will trigger social uproar when the public are made…

France Patrick Pouillot, VP of Life Sciences for TechnipFMC, introduces the business unit as a partner of choice in engineering and construction services for the industry. Pouillot goes on to explain how the business unit in life sciences benefits from the entire group’s strong resource pool and highlights TechnipFMC’s expertise in…

Opinion Holmusk’s Nawal Roy highlights the increasing recognition of the value of real-world evidence (RWE) by both innovative pharma companies and drug regulators and its potential to increase market capture and profitability.   RWE has the potential to expand the market size of a disease and accelerate market capture of a…

France Thomas Clozel, co-founder and CEO of OWKIN, elaborates on how AI can be applied to the pharmaceutical industry to revolutionize today’s drug discovery and development process. He also comments on the challenges facing the sector and how OWKIN is well positioned to overcome questions such as data privacy.   The…

Korea Thibault Janssens, managing director of Bolloré Logistics Korea, shares his expert opinion on the Asian logistics market, and explains how a constant customer-centric focus catering to the specific needs of the pharmaceutical industry has contributed to his firm’s success. Janssens also highlights the potential environmental impact of the logistics industry…

Opinion Tom Achoki of Mass Sciences explores the possibilities that better access to high-quality real-world data will create for accelerating novel drug discovery and ultimately improving patient outcomes.   Proactive decision makers within the biopharmaceutical industry need to find innovative ways to bridge the existing RWD gaps within their organization The…

France Elie Lobel, CEO of Orange Healthcare, explains how digitalization is bringing together stakeholders from across the healthcare continuum, allowing increased information exchange and connectivity. Lobel also gives insight into the latest projects the company is working on to digitally transform healthcare.   Access to healthcare is a critical issue around…

France Christophe Lala, general manager of western Europe for GE Healthcare offers an overview of the current dynamics impacting the French healthcare landscape – namely a shift in structure around care pathways and the hot trend of digitalization. Lala goes on to assess France’s willingness and capability to embrace this technology,…

Opinion The Foundations for Evidence-Based Policy-Making Act, recently signed into law in the USA, stands to make government data more accessible; thereby allowing researchers, statisticians and others inside and outside of government to make better, and evidenced-based, policy decisions. Carla Smith outlines the scope of the Act and its potential implications…